Nektar Therapeutics (NKTR) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC grew its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 87.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,329,281 shares of the biopharmaceutical company’s stock after buying an additional 1,556,352 shares during the period. Janus Henderson Group PLC owned 2.11% of Nektar Therapeutics worth $79,903,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. World Asset Management Inc increased its stake in shares of Nektar Therapeutics by 5.6% during the second quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 539 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Nektar Therapeutics by 14.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 692 shares during the period. Arizona State Retirement System increased its stake in shares of Nektar Therapeutics by 1.0% during the second quarter. Arizona State Retirement System now owns 80,945 shares of the biopharmaceutical company’s stock valued at $1,582,000 after buying an additional 800 shares during the period. Ameritas Investment Partners Inc. increased its stake in shares of Nektar Therapeutics by 7.7% during the second quarter. Ameritas Investment Partners Inc. now owns 13,011 shares of the biopharmaceutical company’s stock valued at $254,000 after buying an additional 929 shares during the period. Finally, Amalgamated Bank increased its stake in shares of Nektar Therapeutics by 8.7% during the second quarter. Amalgamated Bank now owns 20,563 shares of the biopharmaceutical company’s stock valued at $402,000 after buying an additional 1,644 shares during the period. 96.04% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Nektar Therapeutics (NASDAQ NKTR) opened at $56.90 on Friday. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $57.83. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.16. The company had revenue of $152.90 million for the quarter, compared to analysts’ expectations of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The firm’s revenue for the quarter was up 321.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.32) earnings per share. research analysts anticipate that Nektar Therapeutics will post -0.75 EPS for the current year.

In related news, CEO Howard W. Robin sold 83,333 shares of the company’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $24.20, for a total value of $2,016,658.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Christopher A. Kuebler sold 4,000 shares of the company’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $21.86, for a total value of $87,440.00. Following the completion of the sale, the director now directly owns 40,500 shares in the company, valued at $885,330. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 941,427 shares of company stock worth $27,509,448. 6.10% of the stock is owned by insiders.

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group boosted their target price on Nektar Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, November 15th. Cowen assumed coverage on Nektar Therapeutics in a research note on Tuesday, November 7th. They set an “outperform” rating on the stock. Canaccord Genuity assumed coverage on Nektar Therapeutics in a research note on Thursday, November 9th. They set a “buy” rating and a $35.00 target price on the stock. Roth Capital set a $45.00 target price on Nektar Therapeutics and gave the company a “buy” rating in a research note on Monday, November 13th. Finally, Mizuho reissued a “buy” rating and set a $45.00 target price (up from $30.00) on shares of Nektar Therapeutics in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $35.58.

WARNING: This story was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.com-unik.info/2017/12/16/nektar-therapeutics-nktr-shares-bought-by-janus-henderson-group-plc.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

What are top analysts saying about Nektar Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Nektar Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit